Ashland plans to expand its formulation development and GMP contract manufacturing services for solid dispersions and oral solid dosages at its pharmaceutical R&D centre in Wilmington, DE. The expansion, which aims to support early-stage clinical trials, will include spray drying and extrusion processes previously located in Columbia, MD. Ashland said it wool relocate approximately 20 positions from Columbia to Wilmington as a result of the expansion, which is expected to be operational by summer 2014.
Manufacturing Chemist
Wednesday, 6 March 2013
Ashland expands R&D centre
Strong sales at Siegfried
Siegfried has reported a 12% rise in sales to CHF367.8m for the 2012 financial year. During 2012 Siegfried opened a high potency drug production suite in Zofingen, Switzerland, made progress with plans to modernise its production facility. The company plans to start construction of a production plant in Nantong, China, during 2013.
Siegfried
Monday, 4 March 2013
Revenues fall at Codexis
Codexis reported a 29% fall in revenues in 2012 to $88.3m, which it attributed primarily to the termination of its research agreement with Shell. Additionally, product revenues fell 27% to $35.9m primarily due to the timing of orders from innovator pharmaceutical customers. Codexis said it expects to generate royalty revenues and receive a milestone payment in 2013 from its support of the development of argatroban injection for Exela Pharma Sciences partnership with Hikma Pharmaceuticals.
Seeking Alpha
Genmab finally sells facility
Genmab will sell its non-plasma-derived antibody manufacturing facility, in Brooklyn Park, MN, to Baxter Healthcare for $10m. Baxter will also offer employment to Genmab's employees at the site. Genmab has been trying to sell the facility for a number of years and had written off the value to zero.
Genmab
Subscribe to:
Posts (Atom)
